Haleon PLC Director Declaration
October 03 2024 - 4:45AM
RNS Regulatory News
RNS Number : 8361G
Haleon PLC
03 October 2024
Haleon plc: Director
Declaration
3
October 2024: In accordance with
paragraph 6.4.9R of the Listing Rules, Haleon plc hereby gives notification that Alan Stewart
stepped down from the Board of Diageo plc on 26
September 2024.
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a global
leader in consumer health, with a purpose to deliver better
everyday health with humanity. Haleon's product portfolio spans
five major categories - Oral Health, Pain Relief, Respiratory
Health, Digestive Health and Other, and Vitamins, Minerals and
Supplements (VMS). Its long-standing brands - such as Advil,
Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident,
parodontax and Centrum - are built on trusted science, innovation
and deep human understanding.
For more information, please
visit www.haleon.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
RDNMJBLTMTJMMII
Haleon (LSE:HLN)
Historical Stock Chart
From Nov 2024 to Dec 2024
Haleon (LSE:HLN)
Historical Stock Chart
From Dec 2023 to Dec 2024
